X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Lauren Neves

Lauren Neves Lauren Neves is a Director of Policy at PhRMA focusing on the value of cancer medicines, medication adherence, and payment and delivery reform. Prior to joining PhRMA, Lauren earned her law degree and worked as a market access and health policy consultant to health care and pharmaceutical clients.

Recent Posts

How ICER’s assessment of a new class of migraine treatments fails patients

By Lauren Neves  |    July 10, 2018
Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their...   Read More

New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

By Lauren Neves  |    May 31, 2018
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a ...   Read More

RA medicines often demonstrate far greater benefits to patients than initially understood

By Lauren Neves  |    April 5, 2017
In the last decade, new therapies to treat rheumatoid arthritis (RA), a progressive and painful autoimmune disorder, have expanded patients’ treatment options and significantly improved outcomes,...   Read More

How do multiple sclerosis patients define value?

By Lauren Neves  |    February 24, 2017
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value, Real Endpoints...   Read More

Stakeholders raise concerns about ICER’s evidence report for non-small cell lung cancer

By Lauren Neves  |    October 20, 2016
The value of recent advances in non-small cell lung cancer (NSCLC) is undeniable. NSCLC is a devastating illness – 17.7 percent of lung cancer patients survive only five years following their...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the...   Read More

4 recommendations for ICER

By Lauren Neves  |    September 26, 2016
For years, PhRMA has supported policies that ensure health care decisions are grounded in the best available evidence. In our policy solutions for delivering innovative treatments to patients...   Read More

ICYMI: New Oncology Trend Report Highlights the Future Promise of Innovation

By Lauren Neves  |    May 13, 2015
As part of our Healthy Outlook: Conquering Cancer in the 21st Century blog series, we wanted to highlight a new report from IMS Institute for Healthcare Informatics that examines the global market...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates